ARQT (Arcutis) EV/Sales Multiple

Arcutis (ARQT) - corporate logo

Arcutis Biotherapeutics (ARQT) possesses significant pricing power due to the uniqueness of its non-hormonal agents, leveraging patent protection for premium positioning. The company aims to become a dermatology leader by scaling the application of Zoryve across various types of dermatitis. Its reputation as a creator of safe medications ensures patient trust. The EV/Sales multiple reflects the business's maturity, with the current level sitting around 6487.04.

ARQT (Arcutis Biotherapeutics) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Arcutis Biotherapeutics Inc (ARQT)

- market value and analyst target forecast:
- cash and cash flow indicators:
Fundamental company valuation:Arcutis Biotherapeutics - ARQT
Original product of Arcutis

Arcutis Biotherapeutics (ARQT) has built significant intellectual capital value through years of expenditures on clinical trials and patent protection. An analysis of the EV/Sales ratio, which aggregates market capitalization and net debt relative to revenue, allows for an assessment of how effectively these assets are being monetized, where a declining metric amid rising revenues confirms the company's fundamental stability and investment attractiveness.